Symbols / NCNA
NCNA Chart
About
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer; Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer; and Phase 1 modular clinical trial for patients with advanced solid tumors and lung cancer. The company is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is based in Edinburgh, the United Kingdom.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 4.31M |
| Enterprise Value | 44.51B | Income | -27.52M | Sales | — |
| Book/sh | 8.41 | Cash/sh | 0.00 | Dividend Yield | — |
| Payout | 0.00% | Employees | 20 | IPO | — |
| P/E | 0.01 | Forward P/E | -0.24 | PEG | — |
| P/S | — | P/B | 0.27 | P/C | — |
| EV/EBITDA | -2326.55 | EV/Sales | — | Quick Ratio | 4.28 |
| Current Ratio | 4.76 | Debt/Eq | 0.53 | LT Debt/Eq | — |
| EPS (ttm) | 404.87 | EPS next Y | -9.43 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-03-20 16:00 | ROA | -46.39% |
| ROE | -181.81% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 1.91M |
| Shs Float | 20.81B | Short Float | — | Short Ratio | 2.38 |
| Short Interest | — | 52W High | 268.00 | 52W Low | 2.00 |
| Beta | 1.69 | Avg Volume | 66.64K | Volume | 20.16K |
| Target Price | — | Recom | None | Prev Close | $2.11 |
| Price | $2.26 | Change | 7.11% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$2.26
Latest analyst target
3. DCF / Fair value
$-99.89
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.26
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2024-08-19 | reit | Oppenheimer | Outperform → Outperform | $150 |
| 2024-07-23 | reit | Oppenheimer | Outperform → Outperform | $150 |
| 2024-07-22 | main | Oppenheimer | Outperform → Outperform | $150 |
| 2024-04-01 | reit | Oppenheimer | Outperform → Outperform | $4 |
| 2023-11-21 | reit | Oppenheimer | Outperform → Outperform | $4 |
| 2023-09-06 | reit | Truist Securities | Buy → Buy | $6 |
| 2023-08-18 | reit | Oppenheimer | Outperform → Outperform | $4 |
| 2023-05-22 | reit | Oppenheimer | Outperform → Outperform | $4 |
| 2022-09-22 | main | Jefferies | — → Buy | $3 |
| 2022-03-03 | down | Cowen & Co. | Outperform → Market Perform | — |
| 2021-11-24 | main | HC Wainwright & Co. | — → Buy | $9 |
| 2020-12-01 | main | HC Wainwright & Co. | — → Buy | $10 |
| 2020-11-24 | main | HC Wainwright & Co. | — → Buy | $15 |
| 2020-10-22 | init | Truist Securities | — → Buy | $22 |
| 2020-08-21 | main | HC Wainwright & Co. | — → Buy | $17 |
| 2020-07-24 | init | Oppenheimer | — → Outperform | $20 |
| 2020-03-11 | main | HC Wainwright & Co. | — → Buy | $16 |
| 2019-11-15 | reit | HC Wainwright & Co. | — → Buy | $17 |
| 2019-08-19 | init | HC Wainwright & Co. | — → Buy | $20 |
| 2018-10-19 | init | Piper Sandler | — → Overweight | $36 |
- NuCana (NASDAQ: NCNA) reports NUC-7738 activity in PD‑1‑resistant melanoma at ESMO IO - Stock Titan Wed, 10 Dec 2025 08
- NuCana plc Announces Change in American Depository Shares Ratio to Enhance Liquidity and Nasdaq Compliance - Quiver Quantitative Fri, 01 Aug 2025 07
- NuCana stock rises after securing key patent in China for cancer drug - Investing.com Wed, 05 Nov 2025 08
- NuCana (NCNA) Announces $7 Million Direct Offering to Boost Drug Development | NCNA Stock News - GuruFocus ue, 06 May 2025 07
- NuCana Faces Delisting Threat as ADS Price Falls Below Nasdaq Requirements - TipRanks Wed, 09 Jul 2025 07
- 23-Month Progression-Free: NuCana NUC-3373 + Pembrolizumab Shows Durable Response, 81% Tumor Reduction - Stock Titan ue, 14 Oct 2025 07
- Cancer drug developer NuCana hires veteran to run operations - Stock Titan ue, 06 Jan 2026 08
- NuCana's Melanoma Breakthrough: Key Drug Advances to Expansion Trial, Q1 Losses Drop 63% Year-over-Year - Stock Titan Mon, 02 Jun 2025 07
- Cancer Drug Developer NuCana Raises $7M: New Funding to Accelerate Treatment Breakthroughs - Stock Titan ue, 06 May 2025 07
- NCNA Stock Price, News & Analysis | Nucana - Stock Titan hu, 24 Apr 2025 22
- NuCana's Melanoma Drug Breakthrough: 75% Disease Control Rate as Losses Shrink 31% - Stock Titan hu, 20 Mar 2025 07
- NuCana Announces $100 Million ADS Sales Agreement and Successful AGM - TipRanks Mon, 30 Jun 2025 07
- NuCana enters $100 million at-the-market sales agreement for ADS offering - Investing.com Mon, 30 Jun 2025 07
- NuCana to implement 1:200 reverse ADS split to boost share price - Investing.com Fri, 11 Jul 2025 07
- NuCana Reports Q2 2025 Financial Results Highlighting Operating Loss - TipRanks Wed, 20 Aug 2025 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 30.15K | -227.80K | 768.60K | -386.55K |
| TaxRateForCalcs | 0.15 | 0.14 | 0.17 | 0.15 |
| NormalizedEBITDA | -22.68M | -28.89M | -47.58M | -41.88M |
| TotalUnusualItems | 196.00K | -1.66M | 4.59M | -2.54M |
| TotalUnusualItemsExcludingGoodwill | 196.00K | -1.66M | 4.59M | -2.54M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -19.00M | -27.63M | -32.02M | -40.53M |
| ReconciledDepreciation | 522.00K | 575.00K | 732.00K | 942.00K |
| EBITDA | -22.48M | -30.55M | -42.98M | -44.42M |
| EBIT | -23.00M | -31.12M | -43.72M | -45.36M |
| NetInterestIncome | 358.00K | 754.00K | 669.00K | 103.00K |
| InterestIncome | 358.00K | 754.00K | 669.00K | 103.00K |
| NormalizedIncome | -19.16M | -26.20M | -35.85M | -38.38M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -19.00M | -27.63M | -32.02M | -40.53M |
| TotalExpenses | 23.00M | 31.12M | 43.72M | 45.36M |
| TotalOperatingIncomeAsReported | -22.81M | -32.78M | -39.12M | -47.91M |
| DilutedAverageShares | 14.84K | 10.52K | 10.45K | 10.39K |
| BasicAverageShares | 14.84K | 10.52K | 10.45K | 10.39K |
| DilutedEPS | -1.30K | -2.65K | -3.05K | -3.90K |
| BasicEPS | -1.30K | -2.65K | -3.05K | -3.90K |
| DilutedNIAvailtoComStockholders | -19.00M | -27.63M | -32.02M | -40.53M |
| NetIncomeCommonStockholders | -19.00M | -27.63M | -32.02M | -40.53M |
| NetIncome | -19.00M | -27.63M | -32.02M | -40.53M |
| NetIncomeIncludingNoncontrollingInterests | -19.00M | -27.63M | -32.02M | -40.53M |
| NetIncomeContinuousOperations | -19.00M | -27.63M | -32.02M | -40.53M |
| TaxProvision | -3.45M | -4.40M | -6.43M | -7.27M |
| PretaxIncome | -22.45M | -32.03M | -38.45M | -47.80M |
| OtherIncomeExpense | 196.00K | -1.66M | 4.59M | -2.54M |
| SpecialIncomeCharges | -33.00K | -503.00K | -292.00K | -2.81M |
| ImpairmentOfCapitalAssets | 33.00K | 503.00K | 292.00K | 2.81M |
| GainOnSaleOfSecurity | 229.00K | -1.16M | 4.89M | 267.00K |
| NetNonOperatingInterestIncomeExpense | 358.00K | 754.00K | 669.00K | 103.00K |
| InterestIncomeNonOperating | 358.00K | 754.00K | 669.00K | 103.00K |
| OperatingIncome | -23.00M | -31.12M | -43.72M | -45.36M |
| OperatingExpense | 23.00M | 31.12M | 43.72M | 45.36M |
| ResearchAndDevelopment | 18.02M | 25.06M | 36.43M | 36.83M |
| SellingGeneralAndAdministration | 4.99M | 6.06M | 7.29M | 8.53M |
| GeneralAndAdministrativeExpense | 4.99M | 6.06M | 7.29M | 8.53M |
| OtherGandA | 4.99M | 6.06M | 7.29M | 8.53M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | |
|---|---|---|---|---|
| TreasurySharesNumber | 500.00K | 500.00K | 500.00K | |
| OrdinarySharesNumber | 141.54M | 52.36M | 51.87M | 52.18M |
| ShareIssued | 142.04M | 52.86M | 52.37M | 52.18M |
| TotalDebt | 190.00K | 396.00K | 639.00K | 371.00K |
| TangibleBookValue | 3.75M | 12.76M | 36.14M | 63.14M |
| InvestedCapital | 5.95M | 14.89M | 38.50M | 65.55M |
| WorkingCapital | 3.60M | 12.34M | 35.61M | 59.90M |
| NetTangibleAssets | 3.75M | 12.76M | 36.14M | 63.14M |
| CapitalLeaseObligations | 190.00K | 396.00K | 639.00K | 371.00K |
| CommonStockEquity | 5.95M | 14.89M | 38.50M | 65.55M |
| TotalCapitalization | 5.95M | 14.89M | 38.50M | 65.55M |
| TotalEquityGrossMinorityInterest | 5.95M | 14.89M | 38.50M | 65.55M |
| StockholdersEquity | 5.95M | 14.89M | 38.50M | 65.55M |
| GainsLossesNotAffectingRetainedEarnings | 78.42M | 79.17M | 75.87M | 72.14M |
| OtherEquityAdjustments | 78.42M | 79.17M | 75.87M | 72.14M |
| RetainedEarnings | -224.29M | -207.71M | -180.57M | -149.73M |
| AdditionalPaidInCapital | 146.15M | 141.31M | 141.11M | 141.05M |
| CapitalStock | 5.68M | 2.11M | 2.10M | 2.09M |
| CommonStock | 5.68M | 2.11M | 2.10M | 2.09M |
| TotalLiabilitiesNetMinorityInterest | 8.82M | 12.92M | 19.75M | 11.93M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 154.00K | 248.00K | 442.00K | 210.00K |
| LongTermDebtAndCapitalLeaseObligation | 117.00K | 190.00K | 396.00K | 164.00K |
| LongTermCapitalLeaseObligation | 117.00K | 190.00K | 396.00K | 164.00K |
| LongTermProvisions | 37.00K | 58.00K | 46.00K | 46.00K |
| CurrentLiabilities | 8.67M | 12.68M | 19.31M | 11.72M |
| CurrentDebtAndCapitalLeaseObligation | 73.00K | 206.00K | 243.00K | 207.00K |
| CurrentCapitalLeaseObligation | 73.00K | 206.00K | 243.00K | 207.00K |
| CurrentProvisions | 40.00K | 4.10M | ||
| PayablesAndAccruedExpenses | 8.55M | 12.47M | 14.97M | 11.51M |
| CurrentAccruedExpenses | 5.71M | 8.94M | 10.00M | 9.51M |
| Payables | 2.84M | 3.53M | 4.96M | 2.00M |
| TotalTaxPayable | 134.00K | 155.00K | 162.00K | 170.00K |
| AccountsPayable | 2.71M | 3.38M | 4.80M | 1.83M |
| TotalAssets | 14.77M | 27.81M | 58.25M | 77.47M |
| TotalNonCurrentAssets | 2.51M | 2.79M | 3.33M | 5.86M |
| OtherNonCurrentAssets | 2.54M | |||
| NonCurrentDeferredAssets | 113.00K | 143.00K | 103.00K | 60.00K |
| NonCurrentDeferredTaxesAssets | 113.00K | 143.00K | 103.00K | 60.00K |
| GoodwillAndOtherIntangibleAssets | 2.20M | 2.13M | 2.37M | 2.41M |
| OtherIntangibleAssets | 2.20M | 2.13M | 2.37M | 2.41M |
| NetPPE | 197.00K | 521.00K | 866.00K | 851.00K |
| AccumulatedDepreciation | -935.00K | -1.77M | -1.43M | -1.34M |
| GrossPPE | 1.13M | 2.29M | 2.30M | 2.19M |
| OtherProperties | 574.00K | 1.34M | 1.36M | 1.09M |
| MachineryFurnitureEquipment | 558.00K | 955.00K | 941.00K | 1.09M |
| CurrentAssets | 12.27M | 25.02M | 54.92M | 71.61M |
| OtherCurrentAssets | 2.68M | |||
| PrepaidAssets | 877.00K | 1.97M | 3.31M | 3.15M |
| Receivables | 4.64M | 5.83M | 7.02M | 8.20M |
| OtherReceivables | 24.00K | 39.00K | 50.00K | 14.00K |
| TaxesReceivable | 4.62M | 5.79M | 6.97M | 8.19M |
| CashCashEquivalentsAndShortTermInvestments | 6.75M | 17.23M | 41.91M | 60.26M |
| CashAndCashEquivalents | 6.75M | 17.23M | 41.91M | 60.26M |
| CashFinancial | 6.75M | 17.23M | 41.91M | 60.26M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -19.41M | -26.92M | -23.68M | -24.89M |
| RepaymentOfDebt | -223.00K | -270.00K | -227.00K | -296.00K |
| IssuanceOfCapitalStock | 8.73M | 249.00K | 0.00 | 0.00 |
| CapitalExpenditure | -293.00K | -478.00K | -518.00K | -1.06M |
| EndCashPosition | 6.75M | 17.23M | 41.91M | 60.26M |
| BeginningCashPosition | 17.23M | 41.91M | 60.26M | 87.36M |
| EffectOfExchangeRateChanges | 379.00K | -1.08M | 4.85M | 391.00K |
| ChangesInCash | -10.86M | -23.60M | -23.20M | -27.48M |
| FinancingCashFlow | 8.18M | -53.00K | -161.00K | -98.00K |
| CashFlowFromContinuingFinancingActivities | 8.18M | -53.00K | -161.00K | -98.00K |
| NetOtherFinancingCharges | -329.00K | -36.00K | ||
| ProceedsFromStockOptionExercised | 7.00K | 4.00K | 66.00K | 198.00K |
| NetCommonStockIssuance | 8.73M | 249.00K | 0.00 | 0.00 |
| CommonStockIssuance | 8.73M | 249.00K | 0.00 | 0.00 |
| NetIssuancePaymentsOfDebt | -223.00K | -270.00K | -227.00K | -296.00K |
| NetLongTermDebtIssuance | -223.00K | -270.00K | -227.00K | -296.00K |
| LongTermDebtPayments | -223.00K | -270.00K | -227.00K | -296.00K |
| InvestingCashFlow | 79.00K | 2.89M | 120.00K | -3.56M |
| CashFlowFromContinuingInvestingActivities | 79.00K | 2.89M | 120.00K | -3.56M |
| NetOtherInvestingChanges | 2.60M | -2.60M | ||
| InterestReceivedCFI | 372.00K | 770.00K | 638.00K | 101.00K |
| NetIntangiblesPurchaseAndSale | -289.00K | -474.00K | -506.00K | -1.00M |
| PurchaseOfIntangibles | -289.00K | -474.00K | -506.00K | -1.00M |
| NetPPEPurchaseAndSale | -4.00K | -4.00K | -12.00K | -64.00K |
| PurchaseOfPPE | -4.00K | -4.00K | -12.00K | -64.00K |
| OperatingCashFlow | -19.12M | -26.44M | -23.16M | -23.82M |
| CashFlowFromContinuingOperatingActivities | -19.12M | -26.44M | -23.16M | -23.82M |
| TaxesRefundPaid | 4.01M | 5.59M | 7.22M | 9.89M |
| ChangeInWorkingCapital | -2.18M | -1.28M | 3.72M | 4.09M |
| ChangeInPayablesAndAccruedExpense | -3.92M | -2.52M | 3.42M | 3.62M |
| ChangeInPayable | -3.92M | -2.52M | 3.42M | 3.62M |
| ChangeInAccountPayable | -670.00K | -1.43M | 2.97M | -428.00K |
| ChangeInTaxPayable | -3.25M | -1.09M | 442.00K | 4.05M |
| ChangeInIncomeTaxPayable | -3.25M | -1.09M | 442.00K | 4.05M |
| ChangeInPrepaidAssets | 1.74M | 1.23M | 307.00K | 473.00K |
| OtherNonCashItems | -341.00K | -725.00K | -648.00K | -85.00K |
| StockBasedCompensation | 1.65M | 3.86M | 4.89M | 6.66M |
| ProvisionandWriteOffofAssets | 10.00K | -4.11M | 4.10M | 0.00 |
| AssetImpairmentCharge | 33.00K | 503.00K | 292.00K | 2.81M |
| DeferredTax | -3.45M | -4.40M | -6.43M | -7.27M |
| DeferredIncomeTax | -3.45M | -4.40M | -6.43M | -7.27M |
| DepreciationAmortizationDepletion | 522.00K | 575.00K | 732.00K | 942.00K |
| DepreciationAndAmortization | 522.00K | 575.00K | 732.00K | 942.00K |
| AmortizationCashFlow | 185.00K | 208.00K | 732.00K | 535.00K |
| AmortizationOfIntangibles | 185.00K | 208.00K | 732.00K | 535.00K |
| Depreciation | 337.00K | 367.00K | 407.00K | |
| OperatingGainsLosses | -369.00K | 1.18M | -5.01M | -335.00K |
| NetForeignCurrencyExchangeGainLoss | -369.00K | 1.18M | -5.01M | -335.00K |
| NetIncomeFromContinuingOperations | -19.00M | -27.63M | -32.02M | -40.53M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for NCNA
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|